Ipilimumab with or without Nivolumab in Classic Hodgkin Lymphoma with PD after CPI at ASH24
Ajay Major, Assistant Professor of Medicine at the University of Colorado School of Medicine, shared a post on X about a recent abstract by Ann LaCasce et al.
“Ipilimumab with or without Nivolumab in Classic Hodgkin Lymphoma with PD after CPI at ASH24:
- 13 patients, med LOT 4 (all prior PD1, 9 PD1 right before study treatment)
- ORR 23% (no CRs), mPFS 3.3 months
- no ipilimumab non-responders subsequently responded with ipilimumab+nivolumab
Suboptimal approach, but looking forward to correlatives.”
“Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade”
Authors: Reid Merryman, Justin Kline, Robert Redd, Jeremy Abramson, Ann LaCasce et al.
More posts featuring Ajay Major.
Ajay Major is an Assistant Professor of Medicine at the University of Colorado School of Medicine, specializing in lymphoma and CLL/SLL. He is the Founder and President of Pager Publications, as well as the Founder and Editor-in-Chief of in-House. Additionally, he serves as a Reviewer for the Bellevue Literary Review.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023